Conclusions
1 evidence topic · 19 sources
Summary
- Burden and current therapy: past-year GAD prevalence among U.S. adults aged 18 to 65 was 10.0% (95% CI 8.3% to 12.1%). Up to 50% of patients respond inadequately to available agents, SSRI and SNRI discontinuation rates are 20% to 23%, and benzodiazepines carry a class boxed warning.
- Efficacy: in the phase 3 trials Voyage (214 participants) and Panorama (245 participants), a single dose of DT120 ODT 100 µg reduced the Week 12 HAM-A total score by 5.4 and 5.1 points more than placebo (both p<0.0001). These are company topline disclosures; one author states that adoption will depend on full peer-reviewed reporting. The published phase 2b trial (198 participants, capsules) reported a Week 4 difference of -5.0 points (95% CI, -9.6 to -0.4) with 100 µg.
- Safety: with 100 µg versus placebo, TEAEs occurred in 99% versus 69% of participants in Voyage and 94.8% versus 62.9% in Panorama, predominantly on the dosing day. As of September 14, 2026, 14 participants across all DT120 studies had a treatment-emergent serious adverse event, 1 deemed treatment-related.
- Regulatory status: not approved; Breakthrough Therapy designation for GAD (March 2024); NDA filing anticipated in the first half of 2027.
- Monitoring and scheduling: the pivotal trials required 8 hours of monitoring and an end-of-session checklist, which the sponsor intends to inform a potential REMS. Lysergide is Schedule I and must be rescheduled by the DEA and states after approval.
- Economics: price not established; the sponsor stated a corridor of $30,000 to $75,000 per treatment course. The report holds no cost-effectiveness or budget impact model of DT120, only ICER evaluations of esketamine and MDMA-assisted psychotherapy.
- Evidence gaps: peer-reviewed phase 3 reports; functional unblinding (91% and 95% of Panorama participants given 50 µg and 100 µg guessed assignment to drug); active comparators; durability and retreatment beyond 12 weeks (Part B data are open-label and interim); capsule to ODT bridging; registered quality of life outcomes; Part B safety data; and excluded populations.